SHAREHOLDER ALERT: Axsome Therapeutics, Inc. (AXSM) Officers and Directors Face Shareholder Investigation for Alleged Securities Law ViolationsPRNewsWire • 03/14/23
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/23
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in EuropeGlobeNewsWire • 02/22/23
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression DrugInvestorPlace • 02/13/23
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech SprawlingInvestors Business Daily • 02/13/23
Axsome Therapeutics to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/07/23
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27GlobeNewsWire • 01/31/23